Improving health through computation
This article was originally published in Start Up
TwoXAR Inc. wants to help the biopharma industry make good use of big data. The start-up hopes to change the way drug discovery works, with software that can analyze broad arrays of data – chemical compound libraries, gene expression data, protein interaction networks, protein binding databases, patient records and just about anything else related to drug development – and propose a "short list" of drug candidates with a high probability of making it to the clinic.
You may also be interested in...
Californian biopharma, TwoXAR, which is using a computational platform to identify drug candidates, de-risks opportunities through preclinical studies, and progresses drug candidates into the clinic, has raised $10m through a series A financing round.
Parkinson’s disease remains a significant undermet, attractive opportunity for drug developers, including early-stage biotechs. Profiles of MentiNova, Parkure and Prexton Therapeutics.
Gene editing has made a great many headlines of late, and one could be forgiven for thinking the field was saturated, but Homology Medicines Inc. offers something new. Its platform relies on a different mechanism, known as homologous recombination, and the start-up's management team believes the approach can get around some of the potential limitations found in other gene-editing technologies.